249 related articles for article (PubMed ID: 24425867)
21. Mucosal damage induced by preferential COX-1 and COX-2 inhibitors: role of prostaglandins and inflammatory response.
Villegas I; La Casa C; de la Lastra CA; Motilva V; Herrerías JM; Martín MJ
Life Sci; 2004 Jan; 74(7):873-84. PubMed ID: 14659976
[TBL] [Abstract][Full Text] [Related]
22. Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study.
Meek IL; Vonkeman HE; Kasemier J; Movig KL; van de Laar MA
Eur J Clin Pharmacol; 2013 Mar; 69(3):365-71. PubMed ID: 22890587
[TBL] [Abstract][Full Text] [Related]
23. The Molecular Basis for Dual Fatty Acid Amide Hydrolase (FAAH)/Cyclooxygenase (COX) Inhibition.
Palermo G; Favia AD; Convertino M; De Vivo M
ChemMedChem; 2016 Jun; 11(12):1252-8. PubMed ID: 26593700
[TBL] [Abstract][Full Text] [Related]
24. Spectroscopic studies of the binding of Cu(II) complexes of oxicam NSAIDs to alternating G-C and homopolymeric G-C sequences.
Chakraborty S; Bose M; Sarkar M
Spectrochim Acta A Mol Biomol Spectrosc; 2014 Mar; 122():690-7. PubMed ID: 24345609
[TBL] [Abstract][Full Text] [Related]
25. Semi solid matrix formulations of meloxicam and tenoxicam: an in vitro and in vivo evaluation.
Alladi S; Shastri NR
Arch Pharm Res; 2015; 38(5):801-12. PubMed ID: 24752862
[TBL] [Abstract][Full Text] [Related]
26. Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1.
Rimon G; Sidhu RS; Lauver DA; Lee JY; Sharma NP; Yuan C; Frieler RA; Trievel RC; Lucchesi BR; Smith WL
Proc Natl Acad Sci U S A; 2010 Jan; 107(1):28-33. PubMed ID: 19955429
[TBL] [Abstract][Full Text] [Related]
27. The reactions of oxicam and sulfoanilide non steroidal anti-inflammatory drugs with hypochlorous acid: determination of the rate constants with an assay based on the competition with para-aminobenzoic acid chlorination and identification of some oxidation products.
Van Antwerpen P; Dubois J; Gelbcke M; Neve J
Free Radic Res; 2004 Mar; 38(3):251-8. PubMed ID: 15129733
[TBL] [Abstract][Full Text] [Related]
28. Incorporation of NSAIDs in micelles: implication of structural switchover in drug-membrane interaction.
Chakraborty H; Banerjee R; Sarkar M
Biophys Chem; 2003 May; 104(1):315-25. PubMed ID: 12834850
[TBL] [Abstract][Full Text] [Related]
29. Meloxicam: influence on arachidonic acid metabolism. Part II. In vivo findings.
Engelhardt G; Bögel R; Schnitzler C; Utzmann R
Biochem Pharmacol; 1996 Jan; 51(1):29-38. PubMed ID: 8534265
[TBL] [Abstract][Full Text] [Related]
30. Synthesis, anti-inflammatory activity and COX-1/COX-2 inhibition of novel substituted cyclic imides. Part 1: Molecular docking study.
Abdel-Aziz AA; ElTahir KE; Asiri YA
Eur J Med Chem; 2011 May; 46(5):1648-55. PubMed ID: 21388719
[TBL] [Abstract][Full Text] [Related]
31. Interaction of oxicam NSAIDs with DMPC vesicles: differential partitioning of drugs.
Chakraborty H; Roy S; Sarkar M
Chem Phys Lipids; 2005 Dec; 138(1-2):20-8. PubMed ID: 16183046
[TBL] [Abstract][Full Text] [Related]
32. Unusual coordinating behavior by three non-steroidal anti-inflammatory drugs from the oxicam family towards copper(II). Synthesis, X-ray structure for copper(II)-isoxicam, -meloxicam and -cinnoxicam-derivative complexes, and cytotoxic activity for a copper(II)-piroxicam complex.
Cini R; Tamasi G; Defazio S; Hursthouse MB
J Inorg Biochem; 2007 Aug; 101(8):1140-52. PubMed ID: 17592742
[TBL] [Abstract][Full Text] [Related]
33. Forced and long-term degradation assays of tenoxicam, piroxicam and meloxicam in river water. Degradation products and adsorption to sediment.
Jiménez JJ; Muñoz BE; Sánchez MI; Pardo R
Chemosphere; 2018 Jan; 191():903-910. PubMed ID: 29145135
[TBL] [Abstract][Full Text] [Related]
34. COX-2 selectivity and inflammatory processes.
van Ryn J; Trummlitz G; Pairet M
Curr Med Chem; 2000 Nov; 7(11):1145-61. PubMed ID: 11032964
[TBL] [Abstract][Full Text] [Related]
35. Perspective assessment of COX-1 and COX-2 selectivity of nonsteroidal anti-inflammatory drugs from clinical practice: use of genetic function approximation.
Zambre AP; Ganure AL; Shinde DB; Kulkarni VM
J Chem Inf Model; 2007; 47(2):635-43. PubMed ID: 17256838
[TBL] [Abstract][Full Text] [Related]
36. Differentiating oxicam nonsteroidal anti-inflammatory drugs in phosphoglyceride monolayers.
Czapla K; Korchowiec B; Rogalska E
Langmuir; 2010 Mar; 26(5):3485-92. PubMed ID: 20030324
[TBL] [Abstract][Full Text] [Related]
37. Synthesis, COX-1/2 inhibition and antioxidant activities of new oxicam analogues designed as potential chemopreventive agents.
Szczęśniak-Sięga B; Gębczak K; Gębarowski T; Maniewska J
Acta Biochim Pol; 2018; 65(2):199-207. PubMed ID: 29906298
[TBL] [Abstract][Full Text] [Related]
38. Gastric damage induced by subchronic administration of preferential cyclooxygenase-1 and cyclooxygenase-2 inhibitors in rats.
Villegas I; Alarcón de la Lastra C; Martín MJ; Motilva V; La Casa García C
Pharmacology; 2002 Oct; 66(2):68-75. PubMed ID: 12207113
[TBL] [Abstract][Full Text] [Related]
39. Interactions of human serum albumin with meloxicam: characterization of binding site.
Trynda-Lemiesz L; Wiglusz K
J Pharm Biomed Anal; 2010 Jun; 52(2):300-4. PubMed ID: 20089378
[TBL] [Abstract][Full Text] [Related]
40. Scavenging of photogenerated ROS by Oxicams. Possible biological and environmental implications.
Ferrari GV; Natera J; Paulina Montaña M; Muñoz V; Gutiérrez EL; Massad W; Miskoski S; García NA
J Photochem Photobiol B; 2015 Dec; 153():233-9. PubMed ID: 26453988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
